This company listing is no longer active
KZA Stock Overview
Operates as an oncology-focused biotechnology company in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Kazia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.08 |
| 52 Week High | AU$0.24 |
| 52 Week Low | AU$0.047 |
| Beta | 2.13 |
| 1 Month Change | -13.98% |
| 3 Month Change | -46.67% |
| 1 Year Change | -19.19% |
| 3 Year Change | -94.90% |
| 5 Year Change | -78.95% |
| Change since IPO | -95.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| KZA | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -27.3% | -0.2% | -1.1% |
| 1Y | -19.2% | -0.2% | 4.4% |
Return vs Industry: KZA underperformed the Australian Biotechs industry which returned -11.1% over the past year.
Return vs Market: KZA underperformed the Australian Market which returned -0.5% over the past year.
Price Volatility
| KZA volatility | |
|---|---|
| KZA Average Weekly Movement | 28.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.2% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: KZA's share price has been volatile over the past 3 months.
Volatility Over Time: KZA's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Friend | www.kaziatherapeutics.com |
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor.
Kazia Therapeutics Limited Fundamentals Summary
| KZA fundamental statistics | |
|---|---|
| Market cap | AU$18.91m |
| Earnings (TTM) | -AU$20.47m |
| Revenue (TTM) | AU$555.00 |
Over9,999x
P/S Ratio-0.9x
P/E RatioIs KZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KZA income statement (TTM) | |
|---|---|
| Revenue | AU$555.00 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$555.00 |
| Other Expenses | AU$20.47m |
| Earnings | -AU$20.47m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.087 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,687,419.82% |
| Debt/Equity Ratio | 14.9% |
How did KZA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/15 16:53 |
| End of Day Share Price | 2023/11/13 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kazia Therapeutics Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Nazibur Rahman | Maxim Group |